These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9579303)

  • 21. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety of posteroventral pallidotomy for the treatment of advanced Parkinson's disease].
    Molinuevo JL; Valldeoriola F; Rumià J; Nobbe FA; Ferrer E; Tolosa E
    Med Clin (Barc); 2000 Feb; 114(6):205-8. PubMed ID: 10757100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115 patients.
    Parkin SG; Gregory RP; Scott R; Bain P; Silburn P; Hall B; Boyle R; Joint C; Aziz TZ
    Mov Disord; 2002 Jul; 17(4):682-92. PubMed ID: 12210857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
    Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
    Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Confirmation of the antidyskinetic effect of posteroventral pallidotomy by means of an intraoperative apomorphine test.
    Merello M; Cammarota A; Nouzeilles MI; Betti O; Leiguarda R
    Mov Disord; 1998 May; 13(3):533-5. PubMed ID: 9613748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bilateral pallidotomy for treatment of idiopathic Parkinson's disease.
    Li Y; Shi C; Shao M; Ding Y
    Zhonghua Wai Ke Za Zhi; 2000 Mar; 38(3):165-8. PubMed ID: 11832017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Four year follow-up study after unilateral pallidotomy in advanced Parkinson's disease.
    Valldeoriola F; Martínez-Rodríguez J; Tolosa E; Rumià J; Alegret M; Pilleri M; Ferrer E
    J Neurol; 2002 Dec; 249(12):1671-7. PubMed ID: 12529788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pallidotomy versus pallidal stimulation.
    Blomstedt P; Hariz GM; Hariz MI
    Parkinsonism Relat Disord; 2006 Jun; 12(5):296-301. PubMed ID: 16554182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus in advanced Parkinson's disease.
    Kumar R; Lozano AM; Montgomery E; Lang AE
    Mov Disord; 1998; 13 Suppl 1():73-82. PubMed ID: 9613722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
    Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
    Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Motor performance after posteroventral pallidotomy and VIM-thalamotomy in Parkinson's disease: a 1-year follow-up study.
    Aguiar PM; Ferraz HB; Ferraz FP; Saba RA; Hisatugo MK; Andrade LA
    Arq Neuropsiquiatr; 2000 Sep; 58(3B):830-5. PubMed ID: 11018819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge.
    Evans AH; Farrell MJ; Gibson SJ; Helme RD; Lim SY
    Parkinsonism Relat Disord; 2012 Jun; 18(5):514-9. PubMed ID: 22366274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic surgery and Parkinson's disease.
    Narabayashi H
    Stereotact Funct Neurosurg; 1998; 70(2-4):114-21. PubMed ID: 9780407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 10-year follow-up review of patients who underwent Leksell's posteroventral pallidotomy for Parkinson disease.
    Hariz MI; Bergenheim AT
    J Neurosurg; 2001 Apr; 94(4):552-8. PubMed ID: 11302652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Posteroventral pallidotomy in Parkinson's disease.
    Herrera EJ; Viano JC; Cáceres M; Costello G; Suárez M; Suárez JC
    Acta Neurochir (Wien); 2000; 142(2):169-75. PubMed ID: 10795891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The results of drug holiday in Parkinson's disease].
    Martínez F; Castillo J; Castro A; Lema M; Noya M
    Neurologia; 1992 Nov; 7(9):254-9. PubMed ID: 1445710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microelectrode-guided posteroventral medial radiofrequency pallidotomy for Parkinson's disease.
    Kopyov O; Jacques D; Duma C; Buckwalter G; Kopyov A; Lieberman A; Copcutt B
    J Neurosurg; 1997 Jul; 87(1):52-9. PubMed ID: 9202265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.